Clinical Research Directory

Inclusion Criteria: * Age over 18 * Life expectancy \> 12 months * Informed consent understood, signed and patient agrees to all follow-up visits * Chronic type B aortic dissection must be presenting with at least one of the following factors: * Uncontrollable hypertension * Persistent back/chest pain despite medical treatment * Expansion of aortic diameter (false lumen and total diameter) * With risk of progression, i.e. partial thrombosis of the false lumen * Healthy proximal and distal landing zone * Adequate arterial anatomy to perform EVAR by MFM * Healthy branches and collaterals (no stenosis or previously treated by angioplasty) * The patient must be available for the appropriate follow-up visits for the study duration Exclusion Criteria: * Stage 4 or 5 Renal Insufficiency as per K/DOQI clinical practice guidelines for chronic kidney disease (GFR \< 29ml/min/1.73m²) * Dissection or aneurysm rupture, impending or contained rupture * Aortic root aneurysm * Pleural effusion untreated at the procedure time * Prior all surgical procedure within 30 days unless procedure is in preparation for device implantation or planned within 30 days post stent deployment * Myocardial infarction or cerebral vascular accident within 6 weeks of treatment * Presence/suspicion of connective tissue disorders, for example, Marfan or Ehlers-Danlos etc. * Contraindications to the anticoagulant or/ and antiplatelet medications * Thrombocytopenia * Allergic reaction to a contrast agent * Patient with undergoing or planned chemotherapy * History of bleeding disorder (coagulopathy) or thrombophilia * Patient with atrial fibrillation who are under anticoagulation therapy * Presence/suspicion of infection (for example: mycotic aorta) * The use of the MFM with stent-grafts or previously implanted stent-grafts * Pregnant or breastfeeding woman * Patients included in another clinical study * Severe left ventricular dysfunction * Significant arrhythmias * Severe valvular disease